查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1976643

人工淚液市場：2026年至2032年全球預測（依產品類型、活性成分、應用、通路和年齡層別分類）

Artificial Tears Market by Product Type, Active Ingredient, Application, Distribution Channel, Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，人工淚液市場價值將達到 29.9 億美元，到 2026 年將成長至 32.1 億美元，到 2032 年將達到 49 億美元，複合年成長率為 7.27%。

主要市場統計數據
基準年 2025 29.9億美元
預計年份：2026年 32.1億美元
預測年份 2032 49億美元
複合年成長率 (%) 7.27%

人工淚液市場策略概覽：清楚闡述臨床需求促進因素、配方多樣性、成分選擇和不斷發展的通路

本報告清楚闡述了人工淚液市場變化的背景，以及這些變化對生產商、臨床醫生、付款者和經銷商的重要性。人口結構變化、電子設備使用量的增加、隱形眼鏡佩戴率的上升以及前節手術數量的增加，都推動了對緩解症狀的眼科潤滑劑和治療製劑的需求成長。這些臨床和行為因素，加上患者對耐受性、療效和便利性的期望不斷提高，正在推動從傳統滴眼液和眼膏到凝膠和噴霧等各種產品的開發。

識別正在重新定義人工淚液市場的變革性轉變，包括成分創新、包裝演變、數位管道擴張和監管壓力。

由於技術、法規和消費趨勢的融合，該行業正經歷著變革時期。成分創新正在加速，製造商優先考慮透明質酸的各種變體和分子量設計，以最佳化其保留效果和緩解症狀。同時，向無防腐劑配方的轉變正在重塑配方策略和生產要求，而無菌填充技術和高劑量無防腐劑技術的進步則開闢了新的商業性機會。

本報告嚴格評估了美國在 2025 年徵收關稅的累積影響，檢視了供應鏈、籌資策略、價格壓力和製造商的應對措施。

2025年美國徵收的關稅對採購、製造和分銷管道的經濟效益產生了累積影響。對某些進口活性成分、高劑量系統中使用的特殊聚合物以及包裝組件徵收更高的關稅，加劇了依賴全球供應鏈的製造商的成本壓力。因此，採購部門加快了雙重採購策略，並尋求與區域供應商建立更緊密的夥伴關係，以降低貿易波動帶來的風險。對於高分子量透明質酸和用於無防腐劑配方系統的特殊塑膠等原料，關稅加大了上游整合和簽訂長期供應合約的獎勵。

透過詳細的細分分析，了解影響策略的產品類型、活性成分偏好、分銷管道、應用案例和容量形式。

產品細分為將臨床需求和商業性機會轉化為具體的產品和通路策略提供了一個切實可行的觀點。產品類型細分涵蓋眼藥水、凝膠、軟膏和噴霧劑，其中滴眼液進一步細分為乳劑、溶液和懸浮液；凝膠細分為低滲透壓和等滲；軟膏細分為羊毛脂基和凡士林基配方；噴霧劑細分為噴霧和溶液噴霧。這種細分至關重要，因為每種細分類型都有其自身的配方挑戰、儲存要求和患者偏好，因此需要考慮不同的生產和監管因素。

區域分析全面考察了美洲、歐洲、中東和非洲以及亞太地區的需求因素、監管環境、製造地和分銷管道採用趨勢。

區域趨勢導致商業性和營運需求有顯著差異。在美洲，患者就醫便利性、直接面對消費者的行銷以及強大的線上管道應用，與強調產品安全性和標籤清晰度的法規環境並存。面向美洲市場的製造商往往優先考慮快速交貨和全通路庫存策略，該地區仍然是無防腐劑產品和支持長期用藥的訂閱模式實現差異化的關鍵目標市場。

企業洞察老牌製造商、敏捷專家、契約製造製造商和新參與企業如何重組其產品組合、夥伴關係和商業化方法。

人工淚液市場的企業行為體現了策略多樣性：大型成熟製造商注重規模、合規應對力和廣泛的分銷網路，而專業公司和新參與企業則專注於細分市場差異化，例如無防腐劑技術和分子量最佳化的透明質酸。契約製造和合約研發組織正成為日益重要的合作夥伴，能夠快速擴大新配方的生產規模，並靈活應對因關稅變化而導致的採購變化。

為產業領導者提供可操作且優先考慮的建議，以加速成長、降低關稅風險、最佳化分銷，並透過創新增強差異化。

產業領導者必須優先考慮能夠平衡短期韌性和長期差異化的實際措施。首先，應實現關鍵原料和包裝材料籌資策略的多元化，以降低關稅風險和供應中斷的影響，並在監管和成本權衡有利的情況下，探索區域製造夥伴關係和近岸外包。其次，應加快對無防腐劑輸送系統和詳細臨床試驗項目的投資，以檢驗高分子量和低分子量透明質酸的功效，因為臨床差異化在專業人士和消費者的選擇中正變得越來越重要。

透明的調查方法為結論提供了支持：詳細揭露資料來源、專家諮詢、產品映射、供應鏈分析和檢驗方法。

本研究途徑結合了系統性的二手資料分析、有針對性的原始研究以及嚴格的檢驗。二級資訊來源包括同行評審的臨床文獻、監管指南和公開文件、專利狀態、供應商能力報告以及匿名化的管道績效指標。利用這些資訊來源，建構了產品子類型、成分路徑、包裝規格和分銷機制的全面圖譜。原始研究包括對製造商和經銷商進行結構化訪談，訪談對象包括眼科醫師、醫院藥劑師、製藥工程師、包裝工程師和商業負責人，旨在識別實際限制因素和新興策略。

簡明扼要地總結了對相關人員的策略意義，重點在於韌性、以病人為中心的產品設計和營運優先順序。

人工淚液市場正處於變革的關鍵時期，臨床需求、包裝創新、數位化通路和貿易政策相互作用，共同重塑競爭格局。將配方科學（尤其是透明質酸分子變體和無防腐劑技術）與切實可行的供應鏈策略相結合的相關人員，將更有利於滿足臨床醫生的偏好和患者的便利需求。同時，深入了解從醫院藥房到品牌電商等各個分銷管道的特點，對於將產品差異化轉化為永續的市場接受度至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：人工淚液市場：依產品類型分類

  • 眼藥水
  • 凝膠
  • 軟膏
  • 噴

第9章：人工淚液市場（依活性成分分類）

  • 羧甲基纖維素
  • 玻尿酸
  • 聚乙二醇（PEG）
  • 聚乙烯醇

第10章：人工淚液市場：依應用領域分類

  • 過敏性結膜炎
  • 術後支持
  • 乾眼症

第11章：人工淚液市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章：人工淚液市場：依年齡層別分類

  • 成人
  • 兒童

第13章：人工淚液市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：人工淚液市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：人工淚液市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國人工淚液市場

第17章：中國人工淚液市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Alcon Inc.
  • AbbVie Inc.
  • Bausch+Lomb Corporation
  • Abbott Laboratories
  • Johnson & Johnson Services, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Santen Pharmaceutical Co., Ltd.
  • Novartis AG
  • Perrigo Company plc
  • Pfizer Inc.
  • Bayer AG
  • Dr. Reddy's Laboratories Ltd.
  • AFT Pharmaceuticals Limited
  • Aldeyra Therapeutics, Inc.
  • CooperVision, Inc.
  • Eyenovia, Inc.
  • Hilco Vision LLC
  • I-MED Pharma Inc.
  • Lupin Limited
  • Menicon Co., Ltd.
  • Nicox SA
  • Ocular Therapeutix, Inc.
  • Similasan Corporation
  • Sun Pharmaceutical Industries Limited
  • Thea Pharma, Inc.
  • URSAPHARM Arzneimittel GmbH
  • Velocity Pharma LLC
  • Wuhan Yuanda Pharmaceutical Group Co., Ltd.
  • Zhongshan Wanhan Pharmaceutical Co., Ltd.
Product Code: MRR-69324464D1AA

The Artificial Tears Market was valued at USD 2.99 billion in 2025 and is projected to grow to USD 3.21 billion in 2026, with a CAGR of 7.27%, reaching USD 4.90 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.99 billion
Estimated Year [2026] USD 3.21 billion
Forecast Year [2032] USD 4.90 billion
CAGR (%) 7.27%

A strategic introduction to the artificial tears landscape framing clinical demand drivers, formulation diversity, ingredient choices, and evolving distribution pathways

This report opens with a clear framing of what is changing in the artificial tears landscape and why those changes matter to manufacturers, clinicians, payers, and distributors. Demographic shifts, increased digital device exposure, expanded contact lens wear, and higher volumes of anterior segment procedures have all elevated demand for symptomatic ocular lubricants and therapeutic formulations. These clinical and behavioral drivers intersect with heightened patient expectations for tolerability, efficacy, and convenience, prompting product development that spans traditional drops and ointments through to gels and sprays.

Product diversity is more complex than it once was. Market offerings now include drops manufactured as emulsions, solutions, or suspensions; gels differentiated as hypotonic or isotonic; ointments formulated as lanolin-based or petrolatum-based; and sprays delivered as mists or solution sprays. Ingredient strategies layer onto that complexity, with choices between carboxymethylcellulose, hyaluronic acid in high or low molecular weight forms, and preservative-free versus preserved formats that use agents such as benzalkonium chloride, polyquaternium 1, or sodium chlorite. Distribution and dispensing pathways vary from hospital pharmacy to online storefronts and traditional retail, and volume formats span multi-dose containers across several milliliter bands and unit-dose offerings in 0.5 and 1 ml sizes. Together, these dynamics set the stage for an industry that must balance clinical performance, patient convenience, regulatory compliance, and commercial agility.

Identification of transformative shifts redefining artificial tears including ingredient innovation, packaging evolution, digital channel expansion, and regulatory pressures

The industry is undergoing transformative shifts driven by converging technological, regulatory, and consumer trends. Ingredient innovation has accelerated, with manufacturers prioritizing hyaluronic acid variants and molecular-weight engineering to optimize retention and symptom relief. At the same time, the shift toward preservative-free formats is reshaping formulation strategy and manufacturing requirements, while advances in aseptic filling and multi-dose preservative-free technologies are unlocking new commercial options.

Packaging and delivery innovation are equally consequential. Unit-dose formats are gaining traction where sterility and travel convenience are prioritized, while multi-dose containers continue to evolve across size bands to satisfy chronic use and cost sensitivity. The rise of online pharmacies, which includes brand-direct webstores and third-party e-retailers, is changing purchase behaviors and accelerating direct-to-consumer engagement. Retail pharmacy dynamics-where chain and independent outlets follow different stocking and promotional logics-are forcing manufacturers to introduce differentiated go-to-market tactics. Across applications, acoustics of demand have shifted; allergic conjunctivitis and post-surgical care require distinct clinical narratives compared with primary or secondary dry eye management. These structural shifts collectively demand that stakeholders reevaluate product roadmaps, channel investments, and evidence-generation plans to remain competitive.

Rigorous assessment of the cumulative impact of United States tariffs in 2025 on supply chains, sourcing strategies, pricing pressure, and manufacturer responses

The introduction of tariffs in the United States in 2025 has had a cumulative effect that ripples through procurement, manufacturing, and channel economics. Increased duties on certain imported active materials, specialty polymers used in multi-dose systems, and packaging components intensified cost pressures for manufacturers who rely on global supply chains. As a result, procurement teams accelerated dual-sourcing strategies and sought closer partnerships with regional suppliers to reduce exposure to further trade volatility. For inputs such as high molecular weight hyaluronic acid and specialized plastics for preservative-free delivery systems, the tariffs amplified incentives for upstream integration and long-term supply agreements.

These policy-induced cost dynamics also influenced product mix and channel tactics. Manufacturers with narrow margins reassessed the viability of certain lower-priced multi-dose SKUs and explored value engineering to maintain accessibility without degrading product performance. Distributors and retail partners recalibrated assortment strategies, with hospital pharmacies and chain retail outlets negotiating longer-term purchasing terms to stabilize supply. Online channels showed greater flexibility in absorbing incremental costs through tiered pricing or subscription models that smooth consumer spend. In parallel, some companies accelerated investments in domestic manufacturing and contract-filling capacity to sidestep duties, while regulatory teams intensified dialogue with authorities to ensure compliance and expedite approvals for relocated production. The net effect is a more complex commercial environment where supply chain resilience and sourcing strategy are as critical as formulation differentiation.

In-depth segmentation insights decoding product types, active ingredient preferences, distribution channels, application use cases, and volume formats influencing strategy

Segmentation offers a practical lens to translate clinical needs and commercial opportunity into concrete product and channel strategies. Product type segmentation spans drops, gels, ointments, and sprays, with further granularity for drops into emulsion, solution, and suspension formats; gels into hypotonic and isotonic versions; ointments as lanolin-based or petrolatum-based preparations; and sprays delivered as mist or solution spray. This granularity matters because each sub-type has distinct formulation challenges, preservation requirements, and patient preferences, and therefore different manufacturing and regulatory implications.

Active ingredient segmentation is equally influential. Options include carboxymethylcellulose, hyaluronic acid in high and low molecular weight configurations, preservative-free formulations, and preserved variants that deploy benzalkonium chloride, polyquaternium 1, or sodium chlorite. These ingredient decisions drive clinical positioning and influence shelf life, compatibility with packaging, and marketing claims. Distribution channel segmentation encompasses hospital pharmacy, online pharmacy-split between brand websites and e-retailers-retail pharmacy with chain and independent formats, and supermarkets or hypermarkets. Channel choice shapes promotional priorities, reimbursement pathways, and inventory management. Application type segmentation covers allergic conjunctivitis, dry eye syndrome including primary and secondary classifications, irritation relief across mild to severe gradations, and post-surgery care; each application implies different labeling, evidence needs, and clinician engagement strategies. Volume type segmentation differentiates multi-dose and unit-dose formats, with multi-dose broken into under 5 ml, 5 to 10 ml, and over 10 ml sizes, and unit-dose typically at 0.5 ml and 1 ml. These volume distinctions affect user convenience, regulatory categorization for sterility, and cost-to-manufacture calculations. Synthesizing these segmentation dimensions enables more precise targeting of R&D, regulatory dossiers, and commercial rollout plans.

Regional intelligence synthesizing demand drivers, regulatory landscapes, manufacturing footprints, and channel adoption trends across Americas, EMEA, and Asia-Pacific

Regional dynamics produce materially different commercial and operational imperatives. In the Americas, patient access, direct-to-consumer marketing, and strong online channel adoption coexist with a regulatory environment that emphasizes product safety and labeling clarity. Manufacturers serving the Americas often prioritize rapid fulfillment and omnichannel inventory strategies, and the region remains a prime target for differentiated preservative-free offerings and subscription models that support chronic use.

In Europe, the Middle East, and Africa, regulatory complexity and heterogeneous reimbursement systems necessitate tailored market entry strategies and careful compliance planning. European markets tend to emphasize clinical evidence and product quality claims, while certain Middle Eastern and African jurisdictions present opportunities for cost-sensitive multi-dose formats and regionally adapted packaging. In contrast, Asia-Pacific combines a dense manufacturing base with rapidly evolving clinical adoption. The region is notable for production capacity in active ingredients and primary packaging, which supports both global sourcing and localized manufacturing for tariff mitigation. Consumer behaviors also vary widely across the region; online pharmacies and brand websites are expanding quickly in some markets, while traditional retail remains dominant in others. Understanding these regional nuances is essential for aligning manufacturing locations, regulatory timelines, and channel investments with commercial outcomes.

Corporate insights into how established manufacturers, agile specialists, contract manufacturers, and new entrants are reshaping portfolios, partnerships, and commercialization approaches

Company behavior in the artificial tears space reflects strategic diversity: large incumbent manufacturers focus on scale, regulatory depth, and broad distribution networks, while specialist firms and newer entrants concentrate on niche differentiation such as preservative-free technologies or molecular-weight optimized hyaluronic acid. Contract manufacturers and contract development organizations are increasingly important partners, enabling faster scale-up for novel formulations and providing flexibility to respond to tariff-driven sourcing shifts.

Commercial strategies show a mix of consolidation and targeted partnerships. Established players are strengthening direct-to-consumer and professional relationships through co-marketing agreements and clinical evidence generation, while agile specialists invest in digital-first channels and sampling programs to accelerate trial. Packaging and device specialists are partnering with formulators to deliver multi-dose preservative-free solutions and user-friendly unit-dose systems. Across the ecosystem, companies are prioritizing quality systems, supply chain transparency, and traceability to meet regulatory scrutiny and clinician expectations. Successful firms also deploy differentiated evidence programs to substantiate claims for specific indications such as post-surgery care or severe dry eye, recognizing that robust clinical narratives materially affect uptake among prescribers and institutional buyers.

Actionable, prioritized recommendations for industry leaders to accelerate growth, mitigate tariff risks, optimize distribution, and enhance differentiation through innovation

Industry leaders should prioritize a set of practical actions that balance short-term resilience with long-term differentiation. First, diversify sourcing strategies for critical inputs and packaging to mitigate tariff exposure and supply interruptions, and evaluate nearshoring or regional manufacturing partnerships where regulatory and cost trade-offs are favorable. Second, accelerate investment in preservative-free delivery systems and in-depth clinical programs that validate high versus low molecular weight hyaluronic acid benefits, because clinical differentiation is increasingly central to professional and consumer choice.

Third, align commercial models with evolving channel dynamics by strengthening brand-direct channels and forming strategic partnerships with e-retail platforms while preserving relationships with hospital, chain, and independent pharmacies. Fourth, optimize packaging portfolios by balancing unit-dose convenience with the cost efficiencies of multi-dose systems across appropriate size bands, and assess reusable multi-dose technologies that meet sterility expectations. Fifth, invest in sustainability across packaging and supply chain operations to meet both regulatory scrutiny and consumer expectations. Finally, embed tariff-scenario planning into commercial and R&D roadmaps so that product launches, pricing strategies, and contractual commitments remain resilient under shifting trade policies. Prioritizing these steps will support both competitive differentiation and operational stability.

Transparent research methodology detailing data sources, expert consultations, product mapping, supply chain analysis, and validation techniques underpinning conclusions

The research approach combined systematic secondary analysis with targeted primary engagement and rigorous validation. Secondary inputs included peer-reviewed clinical literature, regulatory guidance and public filings, patent landscapes, supplier capability reports, and anonymized channel performance indicators. These sources were used to build a comprehensive mapping of product subtypes, ingredient pathways, volume formats, and distribution mechanics. Primary research comprised structured interviews with ophthalmologists, hospital pharmacists, formulators, packaging engineers, and commercial leaders across manufacturers and distributors to capture practical constraints and emergent strategies.

Data synthesis proceeded through triangulation methods to reconcile varying inputs and to surface consistent patterns across geographies and channel types. Supply chain mapping was used to identify concentrations of risk, particularly for high molecular weight hyaluronic acid and specialized packaging components. Scenario analysis was applied to evaluate the operational implications of tariff-related disruptions and to test the sensitivity of go-to-market models under differing channel mixes. Quality assurance steps included cross-validation of key findings with independent clinical and regulatory experts to ensure accuracy and to sharpen the implications for R&D, operations, and commercial teams. Limitations included variability in proprietary pricing and contract terms that remain confidential to firms, and where applicable, qualitative judgment was applied to interpret those signals.

Concise conclusion synthesizing strategic implications for stakeholders with emphasis on resilience, patient-centric product design, and operational prioritization

The artificial tears sector is at an inflection point where clinical expectations, packaging innovation, digital channels, and trade policy interact to reshape competitive dynamics. Stakeholders who integrate formulation science-especially around hyaluronic acid molecular variants and preservative-free technologies-with pragmatic supply chain strategies will be better positioned to respond to clinician preferences and patient convenience demands. Simultaneously, familiarity with channel nuances from hospital pharmacies through brand e-commerce is essential to translate product differentiation into sustainable adoption.

Operational resilience, particularly in sourcing and manufacturing footprint decisions, will be a defining capability given recent tariff-driven shifts. Companies that proactively align R&D, regulatory evidence generation, and distribution investments will capture disproportionate value by offering clinically substantiated, convenient, and accessible products. Ultimately, the ability to convert segmentation insight into focused portfolios, supported by flexible supply chains and channel-specific commercialization, will determine which organizations lead and which follow as the market evolves.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Artificial Tears Market, by Product Type

  • 8.1. Eye Drops
  • 8.2. Gels
  • 8.3. Ointments
  • 8.4. Sprays

9. Artificial Tears Market, by Active Ingredient

  • 9.1. Carboxymethylcellulose
  • 9.2. Hyaluronic Acid
  • 9.3. Polyethylene Glycol (PEG)
  • 9.4. Polyvinyl Alcohol

10. Artificial Tears Market, by Application

  • 10.1. Allergic Conjunctivitis
  • 10.2. Post Operative Support
  • 10.3. Dry Eye Syndrome

11. Artificial Tears Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Artificial Tears Market, by Age Group

  • 12.1. Adults
  • 12.2. Pediatrics

13. Artificial Tears Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Artificial Tears Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Artificial Tears Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Artificial Tears Market

17. China Artificial Tears Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Alcon Inc.
  • 18.6. AbbVie Inc.
  • 18.7. Bausch + Lomb Corporation
  • 18.8. Abbott Laboratories
  • 18.9. Johnson & Johnson Services, Inc.
  • 18.10. Otsuka Pharmaceutical Co., Ltd.
  • 18.11. Santen Pharmaceutical Co., Ltd.
  • 18.12. Novartis AG
  • 18.13. Perrigo Company plc
  • 18.14. Pfizer Inc.
  • 18.15. Bayer AG
  • 18.16. Dr. Reddy's Laboratories Ltd.
  • 18.17. AFT Pharmaceuticals Limited
  • 18.18. Aldeyra Therapeutics, Inc.
  • 18.19. CooperVision, Inc.
  • 18.20. Eyenovia, Inc.
  • 18.21. Hilco Vision LLC
  • 18.22. I-MED Pharma Inc.
  • 18.23. Lupin Limited
  • 18.24. Menicon Co., Ltd.
  • 18.25. Nicox S.A.
  • 18.26. Ocular Therapeutix, Inc.
  • 18.27. Similasan Corporation
  • 18.28. Sun Pharmaceutical Industries Limited
  • 18.29. Thea Pharma, Inc.
  • 18.30. URSAPHARM Arzneimittel GmbH
  • 18.31. Velocity Pharma LLC
  • 18.32. Wuhan Yuanda Pharmaceutical Group Co., Ltd.
  • 18.33. Zhongshan Wanhan Pharmaceutical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ARTIFICIAL TEARS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ARTIFICIAL TEARS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ARTIFICIAL TEARS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ARTIFICIAL TEARS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ARTIFICIAL TEARS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ARTIFICIAL TEARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY EYE DROPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY EYE DROPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY EYE DROPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY SPRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY SPRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY SPRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY CARBOXYMETHYLCELLULOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY CARBOXYMETHYLCELLULOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY CARBOXYMETHYLCELLULOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY HYALURONIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY HYALURONIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY HYALURONIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY POLYETHYLENE GLYCOL (PEG), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY POLYETHYLENE GLYCOL (PEG), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY POLYETHYLENE GLYCOL (PEG), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY POLYVINYL ALCOHOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY POLYVINYL ALCOHOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY POLYVINYL ALCOHOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY ALLERGIC CONJUNCTIVITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY ALLERGIC CONJUNCTIVITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY ALLERGIC CONJUNCTIVITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY POST OPERATIVE SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY POST OPERATIVE SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY POST OPERATIVE SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY DRY EYE SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY DRY EYE SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY DRY EYE SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS ARTIFICIAL TEARS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA ARTIFICIAL TEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA ARTIFICIAL TEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL TEARS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE ARTIFICIAL TEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST ARTIFICIAL TEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA ARTIFICIAL TEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC ARTIFICIAL TEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN ARTIFICIAL TEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GCC ARTIFICIAL TEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GCC ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. GCC ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 114. GCC ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. GCC ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. GCC ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION ARTIFICIAL TEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS ARTIFICIAL TEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. G7 ARTIFICIAL TEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. G7 ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. G7 ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 132. G7 ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. G7 ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. G7 ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. NATO ARTIFICIAL TEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. NATO ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. NATO ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 138. NATO ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. NATO ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. NATO ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ARTIFICIAL TEARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES ARTIFICIAL TEARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA ARTIFICIAL TEARS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA ARTIFICIAL TEARS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA ARTIFICIAL TEARS MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA ARTIFICIAL TEARS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA ARTIFICIAL TEARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA ARTIFICIAL TEARS MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)